Abstract
Teriparatide (TPT) (C181H291N55O51S2) represents a recombinant molecule acting as human osteoanabolic agent. Transitory hypercalcemia (TH) has been reported in osteoporotic patients treated with daily TPT. Our purpose is to analyze the biochemical features as well as clinical risk factors for fractures in patients with severe osteoporosis treated with TPT who developed TH during first 12 months. This is an observational real-life study. In patients with TH biochemical blood markers like osteocalcin, CrossLaps and P1NP assessed at one year have statistically significant higher values than in subjects associating serum calcium within normal limits under the drug.
Highlights
Daily Practice Treatment for Severe Menopausal OsteoporosisEDWIN SEVER BECHIR1, MIHAELA JANA TUCULINA4*, MARA CARSOTE3, MARILENA BATAIOSU2, MIHAELA RAESCU4, CRISTIAN NIKY CUMPATA4 1 Medicine, Pharmacy, Science and Technology University of Tirgu Mures, Faculty of Dental Medicine, 38 Gheorghe Marinescu Str., 540142, Tirgu Mures, Romania 2 Medicine and Pharmacy University of Craiova, Faculty of Dental Medicine, 2-4 Petru Rares Str., 200349, Craiova, Romania 3 Carol Davila University of Medicine and Pharmacy, C.I
Teriparatide (TPT) (C181H291N55O51S2) represents a recombinant molecule acting as human osteoanabolic agent
The bone promoting medicine has a hepatic metabolism through proteolysis and it requires subcutaneous self-administration every day for 18 months or 24 months depending on protocol [1,7,8]. When it comes to assessment of bone parameters under teriparatide (TPT), an expected anabolic window of blood or urinary bone turnover markers is found in addition to bone mineral density (BMD) increase as detected by central DXA (Dual-Energy X-Ray Absorptiometry) since DXA remains the golden standard in daily practice for osteoporosis assays
Summary
EDWIN SEVER BECHIR1, MIHAELA JANA TUCULINA4*, MARA CARSOTE3, MARILENA BATAIOSU2, MIHAELA RAESCU4, CRISTIAN NIKY CUMPATA4 1 Medicine, Pharmacy, Science and Technology University of Tirgu Mures, Faculty of Dental Medicine, 38 Gheorghe Marinescu Str., 540142, Tirgu Mures, Romania 2 Medicine and Pharmacy University of Craiova, Faculty of Dental Medicine, 2-4 Petru Rares Str., 200349, Craiova, Romania 3 Carol Davila University of Medicine and Pharmacy, C.I. Transitory hypercalcemia (TH) has been reported in osteoporotic patients treated with daily TPT. Our purpose is to analyze the biochemical features as well as clinical risk factors for fractures in patients with severe osteoporosis treated with TPT who developed TH during first 12 months. Transitory hypercalcemia has been reported in osteoporotic patients treated with TPT [12]. Our purpose is to analyse the biochemical features as well as clinical risk factors of osteoporotic fractures in patients with severe osteoporosis treated with TPT who developed transitory hypercalcemia
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
